Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis

被引：0
|
作者：
Toruner, M. [1 ]
Guvenir, T. [1 ]
Er, R. E. [1 ]
Soykan, I. [1 ]
机构：
[1] Ankara Univ, Dept Gastroenterol, Sch Med, Ankara, Turkiye
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P401
引用
收藏
页码：531 / 532
页数：2
相关论文
共 50 条
  • [1] Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
    McLean, Leon P.
    Shea-Donohue, Terez
    Cross, Raymond K.
    IMMUNOTHERAPY, 2012, 4 (09) : 883 - 898
  • [2] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
    Hagan, Matilda
    Cross, Raymond K.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479
  • [3] Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
    Gilroy, Leah
    Allen, Patrick B.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 163 - 172
  • [4] Real-world treatment persistence with vedolizumab in Crohn's disease and ulcerative colitis patients
    Raluy, M.
    Fraeman, K.
    Donaldson, R.
    Reynolds, M.
    Smyth, M.
    Demuth, D.
    Khalid, J. M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S173 - S174
  • [5] Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis
    Ocepek, A.
    Molinari, N.
    Macek, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1847 - I1847
  • [6] Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Feagan, Brian G.
    Loftus, Edward V.
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    GASTROENTEROLOGY, 2013, 144 (05) : S113 - S113
  • [7] Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
    Robert Battat
    Christopher Ma
    Vipul Jairath
    Reena Khanna
    Brian G. Feagan
    Drug Safety, 2019, 42 : 617 - 632
  • [8] Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis
    Hahn, Lindsay
    Beggs, Ashton
    Wahaib, Kristy
    Kodali, Leela
    Kirkwood, Vanessa
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (15) : 1271 - 1278
  • [9] Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease
    Colombel, Jean-Frederic
    Sands, Bruce
    Hanauer, Stephen
    Rutgeerts, Paul
    Sandborn, William
    Danese, Silvio
    D'Haens, Geert
    Panaccione, Remo
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S502 - S503
  • [10] Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis
    Battat, Robert
    Ma, Christopher
    Jairath, Vipul
    Khanna, Reena
    Feagan, Brian G.
    DRUG SAFETY, 2019, 42 (05) : 617 - 632
12345